Nerandomilast, a preferential PDE4B inhibitor with antifibrotic and anti-inflammatory properties, demonstrated a reduction in lung function loss and mortality risk with good tolerability in the phase‐3 FIBRONEER-ILD study, potentially representing a turning point in the management of autoimmune-associated ILD.<h4>Conclusion</h4>Promising results from ongoing clinical studies provide new therapeutic perspectives for SARD-ILD and PPF and may significantly improve prognosis and disease burden in the future. This evidence concerns the gene PDE4B and interstitial lung disease.